FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

Basel, Switzerland, December 18, 2025 – FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response

Basel, Switzerland, 11 August 2025 – FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response.

FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer

Basel, Switzerland, 26 February 2025 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR) pathways, announced today the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.

Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG

Basel, Switzerland, 15 May 2024 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Michael Kauffman as Chairman of the Board.

FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428

Basel, Switzerland, 3 May 2024 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR) pathways, announced today the nomination of its first preclinical development candidate, FORX-428, an inhibitor of Poly(ADP-ribose) glycohydrolase (PARG). FORX-428 has strong best-in-class potential and is being developed for the treatment of solid tumors. IND-enabling activities have already been initiated.

FoRx Therapeutics AG appoints Frank Zenke as Chief Scientific Officer

Basel, Switzerland, 01 August 2023 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Frank Zenke as Chief Scientific Officer.

FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer

Basel, Switzerland, 01 April, 2021 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Tarig Bashir as Chief Executive Officer.

FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry

Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Ulrich Lücking, PhD, as Head of Chemistry.